88 citations,
February 2008 in “Journal of Medicinal Chemistry” Scientists made the first metal-based compounds from a nonsteroidal antiandrogen drug, which showed potential in fighting both hormone-dependent and independent prostate cancer cells.
30 citations,
June 1988 in “Journal of Steroid Biochemistry” Flutamide combined with an LHRH agonist effectively inhibits prostate growth, suggesting it could treat prostate cancer.
10 citations,
November 1997 in “British Journal of Dermatology” RU58841 significantly increases hair growth rate and initiates more hair cycles, but doesn't affect hair thickness, suggesting it could be a new treatment for baldness.
9 citations,
November 2018 in “Acta Clinica Belgica” Don't combine abiraterone and spironolactone for prostate cancer treatment as it may worsen the disease.
8 citations,
January 1987 in “Gynecological Endocrinology” Flutamide, an antiandrogen, has minimal impact on female rat endocrine systems and does not significantly change their reproductive cycles.
204 citations,
February 2000 in “Current Medicinal Chemistry” Antiandrogens like flutamide are effective in treating conditions like prostate cancer and hair loss, but there's a need for more potent versions. Understanding their structure can help develop better treatments.
130 citations,
September 1990 in “Journal of the American Academy of Dermatology” Flutamide effectively reduced excessive hair growth and improved related symptoms in hirsutism patients without significant side effects.
75 citations,
March 1999 in “Fertility and sterility” Finasteride, CPA, and flutamide are all equally effective in reducing excessive hair growth in women.
57 citations,
January 1986 in “The Prostate” The document suggests that targeting the hormone DHT could be a more effective treatment for prostate cancer than targeting testosterone.
42 citations,
April 2011 in “Annals of Pharmacotherapy” Flutamide effectively treats female pattern hair loss with low doses showing good liver tolerance.
38 citations,
June 2015 in “Expert Opinion on Therapeutic Targets” Blocking the prolactin receptor might help treat various diseases, but more research is needed.
35 citations,
January 2012 in “The Journal of Sexual Medicine” Androgen Deprivation Therapy for prostate cancer often reduces sexual function but intermittent therapy may be more tolerable.
34 citations,
December 2015 in “Neuroscience & Biobehavioral Reviews” Some hormone-related drugs may protect brain cells in Parkinson's disease differently in men and women.
27 citations,
December 2015 in “Mayo Clinic Proceedings” The document concludes that lifestyle changes and medical treatments can significantly reduce symptoms of Hidradenitis Suppurativa, a chronic skin condition.
23 citations,
May 2019 in “Expert Opinion on Therapeutic Patents” New androgen receptor modulators show promise for treating diseases like prostate cancer and muscle wasting.
21 citations,
April 2016 in “Journal of Dermatological Treatment” Finasteride may cause mental and sexual side effects, with hand preference and sexual orientation possibly affecting severity.
8 citations,
February 2017 in “Clinical Drug Investigation” Finasteride can cause sexual dysfunction and depression, which may persist and require hormonal treatment.
7 citations,
March 2011 in “Expert Opinion on Drug Safety” Exemestane is effective and safe for treating certain breast cancers, with mild side effects, but needs more research on long-term effects.
June 2023 in “Oriental Journal of Chemistry/Oriental journal of chemistry” New compounds may help treat prostate cancer by reducing cell growth.
February 2023 in “Archives of Dermatological Research” A multi-tiered treatment approach is crucial for managing hidradenitis suppurativa in patients with intellectual and developmental disabilities.
December 2022 in “Research Square (Research Square)” A multi-tiered treatment approach is crucial for managing hidradenitis suppurativa in patients with intellectual and developmental disorders.
2 citations,
June 2022 in “Molecules” Connarus semidecandrus Jack extract promotes hair growth and thickness, reduces prostate cancer cell growth, and could potentially be used as a treatment for hair loss.
1 citations,
March 2022 in “Dermatology Research and Practice” Androgenetic alopecia negatively affects self-esteem and daily stress, especially in young men.
May 2024 in “Journal of clinical medicine” Spironolactone is safe for treating female hair loss, but the safety of other drugs is uncertain.
December 2023 in “Journal of family medicine and primary care” Hair loss in Saudi Arabia causes a low psychosocial impact, with less effect on those without a family history of hair loss.